The EMT signaling pathways in endometrial carcinoma

Clinical and Translational Oncology

Volumn 14, Issue 10, 2012, Pages 715-720

  Colas, Eva ^a,b   Pedrola, Nuria ^a,b   Devis, Laura ^a,b   Ertekin, Tugçe ^a,b   Campoy, Irene ^a,b   Martínez, Elena ^a,b   Llauradó, Marta ^a,b   Rigau, Marina ^a,b   Olivan, Mireia ^a,b   Garcia, Marta ^a,b   Cabrera, Silvia ^c   Gil Moreno, Antonio ^c   Xercavins, Jordi ^c   Castellvi, Josep ^c   Garcia, Angel ^c   Santiago Ramon Y Cajal, S ^c   Moreno Bueno, Gema ^d   Dolcet, Xavier ^e   Alameda, Francesc ^f   Palacios, Jose ^g   Prat, Jaime ^h   Doll, Andreas ^a,b   Matias Guiu, Xavier ^e   Abal, Miguel ⁱ   Reventos, Jaume ^a,b,j   more..

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^d CSIC   (Spain)

^e HOSPITAL ARNAU DE VILANOVA   (Spain)

^f HOSPITAL DEL MAR   (Spain)

^g HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^h HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

ⁱ HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^j UNIVERSITAT INTERNACIONAL DE CATALUNYA   (Spain)

more..

Author keywords

EMT; Endometrial cancer; Invasion

Indexed keywords

BMI1 PROTEIN; MICRORNA; NERVE CELL ADHESION MOLECULE L1; PROGESTERONE RECEPTOR; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR ETV5; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; UVOMORULIN;

CANCER INCIDENCE; CANCER INVASION; ENDOMETRIUM CARCINOMA; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE GENITAL TRACT CANCER; GYNECOLOGIC CANCER; HUMAN; MESENCHYME; MYOMETRIUM; PATHOPHYSIOLOGY; PHENOTYPE; PROGNOSIS; PROTEIN DEPLETION; REVIEW; SIGNAL TRANSDUCTION; TUMOR CELL; UPREGULATION;

CARCINOMA; CELL TRANSFORMATION, NEOPLASTIC; ENDOMETRIAL NEOPLASMS; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; HUMANS; MICRORNAS; MODELS, BIOLOGICAL; NEOPLASM INVASIVENESS; RECEPTORS, PROGESTERONE; SIGNAL TRANSDUCTION;

EID: 84871151974     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-012-0866-3     Document Type: Review

References (71)

1. Bokhman JV (1983) Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 15:10-17
2. Zannoni GF, Scambia G, Gallo D (2011) The dualistic model of endometrial cancer: the challenge of classifying grade 3 endometrioid carcinoma. Gynecol Oncol. doi:10.1016/j.ygyno. 2011.09.036
3. Llauradó M et al (2011) Molecular bases of endometrial cancer: new roles for new actors in the diagnosis and the therapy of the disease. Mol Cell Endocrinol. doi:10.1016/j.mce.2011.10.003
4. Amant F et al (2005) Endometrial cancer. Lancet 366:491-505
5. Yeramian A et al (2012) Endometrial carcinoma: molecular alterations involved in tumor development and progression. Oncogene. doi:10.1038/onc.2012.76
6. Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA Cancer J Clin 62:10-29
7. Abal M et al (2007) Molecular determinants of invasion in endometrial cancer. Clin Transl Oncol 9:272-277
8. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646-674
9. Moreno-Bueno G, Portillo F, Cano A (2008) Transcriptional regulation of cell polarity in EMT and cancer. Oncogene 27:6958-6969
10. Yang J, Weinberg RA (2008) Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev Cell 14:818-829
11. Thiery JP, Morgan M (2004) Breast cancer progression with a Twist. Nat Med 10:777-778
12. Kang Y, Massague J (2004) Epithelial-mesenchymal transitions: twist in development and metastasis. Cell 118:277-279
13. Mueller MM, Fusenig NE (2004) Friends or foes-bipolar effects of the tumour stroma in cancer. Nat Rev Cancer 4:839-849
14. Bhowmick NA, Neilson EG, Moses HL (2004) Stromal fibroblasts in cancer initiation and progression. Nature 432:332-337
15. Barrallo-Gimeno A, Nieto MA (2005) The Snail genes as inducers of cell movement and survival: implications in development and cancer. Development 132:3151-3161
16. De Craene B, Van Roy F, Berx G (2005) Unraveling signaling cascades for the Snail family of transcription factors. Cell Signal 17:535-547
17. Huber M, Kraut N, Beug H (2005) Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr Opin Cell Biol 17:548-558
18. Thiery JP, Sleeman JP (2006) Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol 7:131-142
19. Micalizzi D, Farabaugh S, Ford H (2010) Epithelial-mesenchymal transition in cancer: parallels between normal development and tumor progression. J Mammary Gland Biol Neoplasia 15:117-134
20. Hurt EM, Saykally JN, Anose BM, Kalli KR, Sanders MM (2008) Expression of the ZEB1 (deltaEF1) transcription factor in human: additional insights. Mol Cell Biochem 318:89-99
21. Singh M et al (2008) ZEB1 expression in type I vs type II endometrial cancers: a marker of aggressive disease. Mod Pathol 21:912-923
22. Kyo S et al (2006) High Twist expression is involved in infiltrative endometrial cancer and affects patient survival. Hum Pathol 37:431-438
23. Blechschmidt K et al (2007) The E-cadherin repressor snail plays a role in tumor progression of endometrioid adenocarcinomas. Diagn Mol Pathol 16:222-228
24. Shih H-C et al (2004) Immunohistochemical expression of E-cadherin and betacatenin in the normal and malignant human endometrium: an inverse correlation between E-cadherin and nuclear beta-catenin expression. Anticancer Res 24:3843-3850
25. Scholten AN, Aliredjo R, Creutzberg CL, Smit V T H B (2006) Combined E-cadherin, alpha-catenin, and beta-catenin expression is a favorable prognostic factor in endometrial carcinoma. Int J Gynecol Cancer 16:1379-1385
26. Sakuragi N et al (1994) Decreased E-cadherin expression in endometrial carcinoma is associated with tumor dedifferentiation and deep myometrial invasion. Gynecol Oncol 53:183-189
27. Moreno-Bueno G et al (2003) Abnormalities of E-and P-cadherin and catenin (beta-, gamma-catenin, and p120ctn) expression in endometrial cancer and endometrial atypical hyperplasia. J Pathol 199:471-478
28. Stefansson IM, Salvesen HB, Akslen LA (2004) Prognostic impact of alterations in P-cadherin expression and related cell adhesion markers in endometrial cancer. J Clin Oncol 22:1242-1252
29. Mell LK et al (2004) Prognostic significance of E-cadherin protein expression in pathological stage I-III endometrial cancer. Clin Cancer Res 10:5546-5553
30. Leblanc M et al (2001) Alteration of CD44 and cadherins expression: possible association with augmented aggressiveness and invasiveness of endometrial carcinoma. Virchows Arch 438:78-85
31. Huszar M et al (2010) Up-regulation of L1CAM is linked to loss of hormone receptors and E-cadherin in aggressive subtypes of endometrial carcinomas. J Pathol 220:551-561
32. Pfeifer M et al (2010) L1CAM expression in endometrial carcinomas is regulated by usage of two different promoter regions. BMC Mol Biol 11:64
33. Lee H et al (2012) Immunohistochemical analysis of polycomb group protein expression in advanced gastric cancer. Hum Pathol. doi:10.1016/j.humpath. 2011.12.019
34. Vonlanthen S et al (2001) The bmi-1 oncoprotein is differentially expressed in non-small cell lung cancer and correlates with INK4A-ARF locus expression. Br J Cancer 84:1372-1376
35. Guo B-H et al (2011) Bmi-1 promotes invasion and metastasis, and its elevated expression is correlated with an advanced stage of breast cancer. Mol. Cancer 10:10
36. Glinsky GV, Berezovska O, Glinskii AB (2005) Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer. J Clin Invest 115:1503-1521
37. Zhang F, Sui L, Xin T (2008) Correlations of BMI-1 expression and telomerase activity in ovarian cancer tissues. Exp Oncol 30:70-74
38. Honig A et al (2010) Overexpression of polycomb protein BMI-1 in human specimens of breast, ovarian, endometrial and cervical cancer. Anticancer Res 30:1559-1564
39. Dong P et al (2011) MicroRNA-194 inhibits epithelial to mesenchymal transition of endometrial cancer cells by targeting oncogene BMI-1. Mol Cancer 10:99
40. Stewart C J R, Little L (2009) Immunophenotypic features of MELF pattern invasion in endometrial adenocarcinoma: evidence for epithelial-mesenchymal transition. Histopathology 55:91-101
41. Hanekamp EE et al (2005) Differences in invasive capacity of endometrial cancer cell lines expressing different progesterone receptor isotypes: possible involvement of cadherins. J Soc Gynecol Invest 12:278-284
42. Dai D, Wolf DM, Litman ES, White MJ, Leslie KK (2002) Progesterone inhibits human endometrial cancer cell growth and invasiveness: down-regulation of cellular adhesion molecules through progesterone B receptors. Cancer Res 62:881-886
43. Hanekamp EE et al (2002) Loss of progesterone receptor may lead to an invasive phenotype in human endometrial cancer. Eur J Cancer 38(Suppl 6):S71-S72
44. Van Der Horst PH et al (2012) Progesterone inhibits epithelial-to- mesenchymal transition in endometrial cancer. PLoS One 7(1):e30840
45. Fujita N et al (2003) MTA3, a Mi-2/NuRD complex subunit, regulates an invasive growth pathway in breast cancer. Cell 113:207-219
46. Dandachi N et al (2001) Co-expression of tenascin-C and vimentin in human breast cancer cells indicates phenotypic transdifferentiation during tumour progression: correlation with histopathological parameters, hormone receptors, and oncoproteins. J Pathol 193:181-189
47. Ehrlich CE, Young PC, Stehman FB, Sutton GP, Alford WM (1988) Steroid receptors and clinical outcome in patients with adenocarcinoma of the endometrium. Am J Obstet Gynecol 158:796-807
48. Jeon Y-T et al (2006) Steroid receptor expressions in endometrial cancer: clinical significance and epidemiological implication. Cancer Lett 239:198-204
49. Thigpen JT et al (1999) Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group. J Clin Oncol 17:1736-1744
50. Hanekamp EE et al (2003) Consequences of loss of progesterone receptor expression in development of invasive endometrial cancer. Clin Cancer Res 9:4190-4199
51. Wang Y et al (2009) Progesterone inhibition of Wnt/beta-catenin signaling in normal endometrium and endometrial cancer. Clin Cancer Res 15:5784-5793
52. Massagué J (2008) TGFbeta in Cancer. Cell 134:215-230
53. Derynck R, Zhang YE (2003) Smad-dependent and Smad-independent pathways in TGF-beta family signaling. Nature 425:577-584
54. Parekh TV et al (2002) Transforming growth factor beta signaling is disabled early in human endometrial carcinogenesis concomitant with loss of growth inhibition. Cancer Res 62:2778-2790
55. Muinelo-Romay L et al (2011) High-risk endometrial carcinoma profiling identifies TGF-b1 as a key factor in the initiation of tumor invasion. Mol Cancer Ther 10:1357-1366
56. Lei X, Wang L, Yang J, Sun L-Z (2009) TGFbeta signaling supports survival and metastasis of endometrial cancer cells. Cancer Manag Res 2009:15-24
57. De Launoit Y et al (2006) The Ets transcription factors of the PEA3 group: transcriptional regulators in metastasis. Biochim Biophys Acta 1766:79-87
58. Graves BJ, Petersen JM (1998) Specificity within the ets family of transcription factors. Adv Cancer Res 75:1-55
59. Planaguma J et al (2005) Up-regulation of ERM/ETV5 correlates with the degree of myometrial infiltration in endometrioid endometrial carcinoma. J Pathol 207:422-429
60. Llauradó M et al (2012) ETV5 transcription factor is overexpressed in ovarian cancer and regulates cell adhesion in ovarian cancer cells. Int J Cancer 130:1532-1543
61. Colas E et al (2012) ETV5 cooperates with LPP as a sensor of extracellular signals and promotes EMT in endometrial carcinomas. Oncogene. doi:10.1038/onc.2011.632
62. Monge M et al (2007) ERM/ETV5 up-regulation plays a role during myometrial infiltration through matrix metalloproteinase-2 activation in endometrial cancer. Cancer Res 67:6753-6759
63. Monge M et al (2009) Proteomic approach to ETV5 during endometrial carcinoma invasion reveals a link to oxidative stress. Carcinogenesis 30:1288-1297
64. Monge M et al (2009) Subtractive proteomic approach to the endometrial carcinoma invasion front. J Proteome Res 8:4676-4684
65. Ebert MS, Sharp PA (2012) Roles for MicroRNAs in conferring robustness to biological processes. Cell 149:515-524
66. Bartel DP (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116:281-297
67. Lujambio A, Lowe SW (2012) The microcosmos of cancer. Nature 482:347-355
68. Castilla MA et al (2011) Micro-RNA signature of the epithelial- mesenchymal transition in endometrial carcinosarcoma. J Pathol 223:72-80
69. Kong W et al (2008) MicroRNA-155 is regulated by the transforming growth factor beta/Smad pathway and contributes to epithelial cell plasticity by targeting RhoA. Mol Cell Biol 28:6773-6784
70. Howe EN, Cochrane DR, Richer JK (2011) Targets of miR-200c mediate suppression of cell motility and anoikis resistance. Breast Cancer Res 13:R45
71. Cano A, Nieto MA (2008) Non-coding RNAs take centre stage in epithelial-tomesenchymal transition. Trends Cell Biol 18:357-359